1-9 of 9
Tapan Kadia
Close
Sort by
Journal Articles

Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study

Clinical Trials & Observations
Marco Herling, Claire Dearden, Francesco Zaja, Dima El-Sharkawi, Wei Ding, Mar Bellido, Amit Khot, Lidwine Tick, Eric Jacobsen, Toby A. Eyre, Damien Roos-Weil, Tapan Kadia, Elisa Lucchini, Natali Pflug, Matthew S. Davids, German Pena, Nabanita Mukherjee, Mohamed Badawi, Tamas Vizkelety, Philipp B. Staber
Journal: Blood Advances
Blood Adv (2024) 8 (4): 842–845.
https://doi.org/10.1182/bloodadvances.2023012248
Published: 2024
Includes: Supplemental data
Journal Articles

Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity

Alexandre Bazinet, Tapan Kadia, Nicholas J. Short, Gautam Borthakur, Sa A. Wang, Wei Wang, Sanam Loghavi, Jeffrey Jorgensen, Keyur Patel, Courtney DiNardo, Naval Daver, Yesid Alvarado, Fadi G. Haddad, Sherry Pierce, Graciela Nogueras Gonzalez, Abhishek Maiti, Koji Sasaki, Musa Yilmaz, Philip Thompson, William Wierda, Guillermo Garcia-Manero, Michael Andreeff, Elias Jabbour, Marina Konopleva, Xuelin Huang, Hagop Kantarjian, Farhad Ravandi
Journal: Blood Advances
Blood Adv (2023) 7 (13): 3284–3296.
https://doi.org/10.1182/bloodadvances.2022009391
Published: 2023
Includes: Supplemental data
Journal Articles

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2 -mutant myelodysplastic syndrome

Clinical Trials & Observations
Courtney D. DiNardo, Sangeetha Venugopal, Curtis Lachowiez, Koichi Takahashi, Sanam Loghavi, Guillermo Montalban-Bravo, Xuemei Wang, Hetty Carraway, Mikkael Sekeres, Ameenah Sukkur, Danielle Hammond, Kelly Chien, Abhishek Maiti, Lucia Masarova, Koji Sasaki, Yesid Alvarado, Tapan Kadia, Nicholas J. Short, Naval Daver, Gautam Borthakur, Farhad Ravandi, Hagop M. Kantarjian, Bhumika Patel, Amy Dezern, Gail Roboz, Guillermo Garcia-Manero
Journal: Blood Advances
Blood Adv (2023) 7 (11): 2378–2387.
https://doi.org/10.1182/bloodadvances.2022008378
Published: 2023
Includes: Supplemental data
Journal Articles

A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL

Clinical Trials & Observations
Nitin Jain, Jayastu Senapati, Beenu Thakral, Alessandra Ferrajoli, Philip Thompson, Jan Burger, Sreyashi Basu, Tapan Kadia, Naval Daver, Gautam Borthakur, Marina Konopleva, Naveen Pemmaraju, Erin Parry, Catherine J. Wu, Joseph Khoury, Carlos Bueso-Ramos, Naveen Garg, Xuemei Wang, Wanda Lopez, Ana Ayala, Susan O’Brien, Hagop Kantarjian, Michael Keating, James Allison, Padmanee Sharma, William Wierda
Journal: Blood Advances
Blood Adv (2023) 7 (10): 1958–1966.
https://doi.org/10.1182/bloodadvances.2022008790
Published: 2023
Includes: Supplemental data
Journal Articles

Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD

Naveen Pemmaraju, Nathaniel R. Wilson, Guillermo Garcia-Manero, Koji Sasaki, Joseph D. Khoury, Nitin Jain, Gautam Borthakur, Farhad Ravandi, Naval Daver, Tapan Kadia, Courtney DiNardo, Elias Jabbour, Sherry Pierce, Muzaffar Qazilbash, Marina Konopleva, Hagop Kantarjian
Journal: Blood Advances
Blood Adv (2022) 6 (10): 3027–3035.
https://doi.org/10.1182/bloodadvances.2021006645
Published: 2022
Includes: Supplemental data
Journal Articles

Outcomes of acute lymphoblastic leukemia with KMT2A ( MLL ) rearrangement: the MD Anderson experience

Clinical Trials & Observations
Guillaume Richard-Carpentier, Hagop M. Kantarjian, Guilin Tang, C. Cameron Yin, Joseph D. Khoury, Ghayas C. Issa, Fadi Haddad, Nitin Jain, Farhad Ravandi, Nicholas J. Short, Courtney D. DiNardo, Koichi Takahashi, Marina Y. Konopleva, Naval G. Daver, Tapan Kadia, Guillermo Garcia-Manero, Rebecca Garris, Susan O’Brien, Elias Jabbour
Journal: Blood Advances
Blood Adv (2021) 5 (23): 5415–5419.
https://doi.org/10.1182/bloodadvances.2021004580
Published: 2021
Journal Articles

Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax

Clinical Trials & Observations
Curtis A. Lachowiez, Sanam Loghavi, Ken Furudate, Guillermo Montalban-Bravo, Abhishek Maiti, Tapan Kadia, Naval Daver, Gautam Borthakur, Naveen Pemmaraju, Koji Sasaki, Yesid Alvarado, Musa Yilmaz, Nicholas J. Short, Kelly Chien, Maro Ohanian, Sherry Pierce, Keyur P. Patel, Elias Jabbour, Farhad Ravandi, Hagop M. Kantarjian, Guillermo Garcia-Manero, Koichi Takahashi, Marina Y. Konopleva, Courtney D. DiNardo
Journal: Blood Advances
Blood Adv (2021) 5 (8): 2173–2183.
https://doi.org/10.1182/bloodadvances.2020004173
Published: 2021
Includes: Supplemental data
Journal Articles

NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy

Clinical Trials & Observations
Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Koji Sasaki, Keyur Patel, Irene Ganan-Gomez, Elias Jabbour, Tapan Kadia, Farhad Ravandi, Courtney DiNardo, Gautham Borthakur, Koichi Takahashi, Marina Konopleva, Rami S. Komrokji, Amy DeZern, Teodora Kuzmanovic, Jaroslaw Maciejewski, Sherry Pierce, Simona Colla, Mikkael A. Sekeres, Hagop Kantarjian, Carlos Bueso-Ramos, Guillermo Garcia-Manero
Journal: Blood Advances
Blood Adv (2019) 3 (6): 922–933.
https://doi.org/10.1182/bloodadvances.2018026989
Published: 2019
Includes: Supplemental data
Journal Articles

Co-occurrence of FLT3 -TKD and NPM1 mutations defines a highly favorable prognostic AML group

Clinical Trials & Observations
Prajwal Boddu, Hagop Kantarjian, Gautam Borthakur, Tapan Kadia, Naval Daver, Sherry Pierce, Michael Andreeff, Farhad Ravandi, Jorge Cortes, Steven M. Kornblau
Journal: Blood Advances
Blood Adv (2017) 1 (19): 1546–1550.
https://doi.org/10.1182/bloodadvances.2017009019
Published: 2017
Includes: Supplemental data